+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rosacea - Pipeline Review, H1 2020

  • ID: 5024775
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 90 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aiviva BioPharma Inc
  • AOBiome LLC
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Hovione FarmaCiencia SA
  • MORE
Rosacea - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 10, 5 and 7 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aiviva BioPharma Inc
  • AOBiome LLC
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Hovione FarmaCiencia SA
  • MORE
  • Introduction
  • Report Coverage
  • Rosacea - Overview
  • Rosacea - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Rosacea - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Rosacea - Companies Involved in Therapeutics Development
  • Accuitis Pharmaceuticals Inc
  • Afecta Pharmaceuticals Inc
  • Aiviva BioPharma Inc
  • AlfaSigma SpA
  • AOBiome LLC
  • Biomimetix JV LLC
  • BioPharmX Inc
  • Botanix Pharmaceuticals Ltd
  • Cellix Bio Pvt Ltd
  • Cutanea Life Sciences Inc
  • Dermata Therapeutics LLC
  • ELORAC Inc
  • Emeriti Pharma AB
  • GlycoMira Therapeutics Inc
  • Hovione FarmaCiencia SA
  • Maruho Co Ltd
  • Matrisys Bioscience Inc
  • Menlo Therapeutics Inc
  • Sol-Gel Technologies Ltd
  • Sunny Pharmtech Inc
  • Tarsus Pharmaceuticals Inc
  • TWi Biotechnology Inc
  • Rosacea - Drug Profiles
  • AC-701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACUD-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AFX-4031 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AIV-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • B-244 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • benzoyl peroxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMX-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BPX-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BTX-1702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • carbamide peroxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLX-1621 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLXDER-621 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLXDER-622 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLXDER-623 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DMT-210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • doxycycline hyclate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-0003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FMX-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-0111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HY-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-1220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MSB-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • omiganan pentahydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • phenylbutyrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rifaximin DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rosacea - Dormant Projects
  • Rosacea - Discontinued Products
  • Rosacea - Product Development Milestones
  • Featured News & Press Releases
  • Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea
  • Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
  • Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology
  • Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
  • Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
  • Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103
  • Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea
  • Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
  • Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference
  • Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
  • Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea
  • Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
  • Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
  • May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
  • Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Rosacea, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by Aiviva BioPharma Inc, H1 2020
  • Rosacea - Pipeline by AlfaSigma SpA, H1 2020
  • Rosacea - Pipeline by AOBiome LLC, H1 2020
  • Rosacea - Pipeline by Biomimetix JV LLC, H1 2020
  • Rosacea - Pipeline by BioPharmX Inc, H1 2020
  • Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
  • Rosacea - Pipeline by Cellix Bio Pvt Ltd, H1 2020
  • Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2020
  • Rosacea - Pipeline by Dermata Therapeutics LLC, H1 2020
  • Rosacea - Pipeline by ELORAC Inc, H1 2020
  • Rosacea - Pipeline by Emeriti Pharma AB, H1 2020
  • Rosacea - Pipeline by GlycoMira Therapeutics Inc, H1 2020
  • Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2020
  • Rosacea - Pipeline by Maruho Co Ltd, H1 2020
  • Rosacea - Pipeline by Matrisys Bioscience Inc, H1 2020
  • Rosacea - Pipeline by Menlo Therapeutics Inc, H1 2020
  • Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2020
  • Rosacea - Pipeline by Sunny Pharmtech Inc, H1 2020
  • Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by TWi Biotechnology Inc, H1 2020
  • Rosacea - Dormant Projects, H1 2020
  • Rosacea - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Rosacea - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Rosacea, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Accuitis Pharmaceuticals Inc
  • Afecta Pharmaceuticals Inc
  • Aiviva BioPharma Inc
  • AlfaSigma SpA
  • AOBiome LLC
  • Biomimetix JV LLC
  • BioPharmX Inc
  • Botanix Pharmaceuticals Ltd
  • Cellix Bio Pvt Ltd
  • Cutanea Life Sciences Inc
  • Dermata Therapeutics LLC
  • ELORAC Inc
  • Emeriti Pharma AB
  • GlycoMira Therapeutics Inc
  • Hovione FarmaCiencia SA
  • Maruho Co Ltd
  • Matrisys Bioscience Inc
  • Menlo Therapeutics Inc
  • Sol-Gel Technologies Ltd
  • Sunny Pharmtech Inc
  • Tarsus Pharmaceuticals Inc
  • TWi Biotechnology Inc
Note: Product cover images may vary from those shown
Adroll
adroll